Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Boost from Citigroup

Key Points

• Citigroup raised Regeneron’s price target from $740 to $825 while maintaining a “neutral” rating, implying approximately 11% downside from the stock’s reported $927.89 price.
• Analyst sentiment remains broadly positive: Regeneron has a consensus “Moderate Buy” rating and an average price target of $850.83, with UBS and Canaccord among firms assigning “buy” ratings.
• Shares rose 13.3% after the company reported quarterly EPS of $20.07 and revenue of $5.12 billion, exceeding estimates of $16.42 EPS and $4.56 billion in revenue; revenue increased 36.3% year over year.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price target increased by analysts at Citigroup from $740.00 to $825.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has a "neutral" rating on the biopharmaceutical company's stock. Citigroup's target price would suggest a potential downside of 11.09% from the stock's current price.

REGN has been the topic of several other reports. Leerink Partners raised their target price on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a "market perform" rating in a research report on Monday, August 17th. UBS Group upgraded Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and upped their target price for the company from $660.00 to $978.00 in a research note on Thursday, October 15th. Robert W. Baird raised their target price on Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the stock a "neutral" rating in a report on Friday, July 31st. Canaccord Genuity Group raised their price target on Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Royal Bank Of Canada upped their price target on Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the company a "sector perform" rating in a research report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $850.83.

Regeneron Pharmaceuticals Stock Up 13.3%

Shares of NASDAQ:REGN traded up $109.12 during trading on Friday, hitting $927.89. The company's stock had a trading volume of 2,870,601 shares, compared to its average volume of 822,542. The company has a market capitalization of $95.54 billion, a PE ratio of 22.93, a P/E/G ratio of 1.37 and a beta of 0.16. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. Regeneron Pharmaceuticals has a fifty-two week low of $591.52 and a fifty-two week high of $935.35. The business has a 50 day moving average price of $791.28 and a two-hundred day moving average price of $737.25.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $16.42 by $3.65. The firm had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.56 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The business's revenue was up 36.3% on a year-over-year basis. During the same quarter last year, the company posted $11.83 earnings per share. As a group, research analysts expect that Regeneron Pharmaceuticals will post 49.10 EPS for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, insider Andrew J. Murphy sold 4,147 shares of the company's stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the transaction, the insider owned 47,833 shares in the company, valued at $36,960,559.10. This represents a 7.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the company's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director owned 1,703 shares of the company's stock, valued at $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,093 shares of company stock valued at $6,506,845 in the last ninety days. Corporate insiders own 6.97% of the company's stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently modified their holdings of REGN. BlackRock Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $5,682,636,000. State Street Corp increased its position in Regeneron Pharmaceuticals by 3.6% during the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company's stock worth $3,014,621,000 after buying an additional 170,210 shares during the period. Bank of America Corp DE increased its stake in Regeneron Pharmaceuticals by 8.5% in the second quarter. Bank of America Corp DE now owns 1,291,053 shares of the biopharmaceutical company's stock valued at $805,023,000 after acquiring an additional 101,469 shares during the last quarter. Amundi raised its stake in shares of Regeneron Pharmaceuticals by 0.4% during the second quarter. Amundi now owns 1,013,540 shares of the biopharmaceutical company's stock valued at $631,983,000 after acquiring an additional 3,742 shares during the last quarter. Finally, Legal & General Group Plc acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $473,872,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations: Regeneron reported $5.12 billion in revenue, up 36.3% year over year and well above the approximately $4.56 billion analyst consensus. Non-GAAP EPS was $20.07, compared with estimates near $16.42 and $11.83 a year earlier. REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
• Positive Sentiment: Strong commercial performance: Sanofi-partnered Dupixent generated robust demand, while U.S. Eylea HD sales increased 62% to $699 million and global Libtayo sales rose 51% to $550 million. The results suggest Regeneron’s product portfolio is offsetting competitive and pricing pressures in older treatments. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Pipeline and strategic momentum: Regeneron highlighted progress toward upcoming FDA catalysts, expanded its Sanofi collaboration with next-generation long-acting immunology antibodies and received a $1 billion upfront payment to be recognized as collaboration revenue. A new Phase 2 cemiplimab combination study also expands its skin-cancer pipeline. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
• Neutral Sentiment: Management characterized 2026 as potentially one of Regeneron’s strongest years, and analysts have raised some expectations following the earnings beat. Investors will now focus on whether Dupixent growth and new launches can remain durable.
• Negative Sentiment: Eylea 2 mg remains exposed to biosimilar competition, while at least one analyst recently lowered Regeneron’s price target from $900 to $850. After the sharp upward move, valuation and the need for continued execution could create near-term volatility. Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.